围放疗期化疗联合调强放疗及每周多西他赛治疗不可手术非转移性胃癌的多中心2期研究
这项多中心2期研究评估了同步放化疗联合放疗前后化疗对未接受手术的非转移性胃癌患者的疗效与可行性:36例可评估患者的临床完全缓解率为36%(95%CI 19%-53%),总缓解率为83%(95%CI 75%-97%),中位生存期为25.8个月,估计2年生存率为52%。达到临床完全缓解与总生存和无进展生存显著改善相关(P=.004和P=.003),方案可耐受。
要点
- 36例可评估患者临床完全缓解率36%(95%CI 19%-53%),总缓解率83%(95%CI 75%-97%)。
- 中位生存期25.8个月(95%CI 7.1-44.5个月),估计2年生存率52%(95%CI 38%-67%)。
- 达到临床完全缓解者总生存(P=.004)与无进展生存(P=.003)显著更优。
核心结论
- 围放疗期化疗联合同步放化疗(CCRT)方案在不可手术或医学上不可切除的胃癌患者中可耐受且疗效有前景。
研究设计与样本
- 多中心2期研究,36例可评估的非转移性胃癌患者,均未接受手术。
- 患者分3组:21例因合并症不适合手术(组1),8例不可切除(组2),7例拒绝手术(组3)。
- 放疗前与放疗后化疗各最多2个21天周期:多西他赛37.5 mg/m2第1、8天,顺铂25 mg/m2第1-3天,氟尿嘧啶750 mg/m2持续输注第1-5天。
- CCRT于第43天开始:调强放疗50.4 Gy同步每周多西他赛20 mg/m2共6周。
主要发现
- 36例可评估患者临床完全缓解率为36%(95%CI 19%-53%),总缓解率为83%(95%CI 75%-97%)。
- 中位生存时间25.8个月(95%CI 7.1-44.5个月),估计2年生存率52%(95%CI 38%-67%)。
- 组1、组2、组3的估计中位OS分别为37.0个月(95%CI 7.9-66.1个月)、17.7个月(95%CI 7.8-27.6个月)、38.9个月(95%CI 16.6-58.3个月);2年OS率分别为52%(95%CI 31%-73%)、20%(95%CI 0%-49%)、67%(95%CI 30%-100%)。
- 达到临床完全缓解与总生存显著改善相关(P=.004),与无进展生存显著改善相关(P=.003)。
- 化疗阶段最常见的3级及以上毒性为中性粒细胞减少;CCRT期间常见3/4级毒性为恶心和呕吐。
临床怎么用
- 对于因合并症、不可切除或拒绝手术而未行手术的非转移性胃癌患者,可考虑围放疗期化疗联合调强放疗同步每周多西他赛的方案。
- 治疗期间需重点监测化疗阶段的中性粒细胞减少及CCRT期间的恶心呕吐。
- 达到临床完全缓解可能提示生存获益,可作为疗效评估与随访关注指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the efficacy and feasibility of concurrent chemoradiation therapy (CCRT) plus preradiation and postradiation chemotherapy for patients with nonmetastatic gastric carcinoma who do not undergo surgery. METHODS AND MATERIALS: Patients with inoperable (due to medical comorbid conditions or patient's refusal to undergo surgery) or unresectable gastric cancer received up to 2 21-day cycles of preradiation and postradiation chemotherapy (docetaxel 37.5 mg/m2 on days 1 and 8, cisplatin 25 mg/m2 on days 1-3, and a continuous infusion of fluorouracil [FU] 750 mg/m2 on days 1-5), respectively. CCRT between preradiation and postradiation chemotherapy was initiated on day 43 and consisted of intensity modulated radiation therapy (50.4 Gy) plus concurrent docetaxel 20 mg/m2 weekly for 6 weeks. RESULTS: 36 patients were evaluable; 21 patients with comorbid conditions were unsuitable for surgery (group 1), 8 had unresectable disease (group 2), and 7 refused surgery (group 3). The clinical complete response (cCR) rate for the 36 evaluable patients was 36% (95% confidence interval [CI], 19%-53%) and the overall response rate was 83% (95% CI, 75%-97%). The median survival time and estimated 2-year survival rate were 25.8 months (95% CI, 7.1-44.5 months) and 52% (95% CI, 38%-67%), respectively. The estimated median OS and 2-year OS rates for groups 1, 2, and 3 were 37.0 months (95% CI, 7.9-66.1 months) and 52% (95% CI, 31%-73%), 17.7 months (95% CI, 7.8-27.6 months) and 20% (95% CI, 0%-49%), and 38.9 months (95% CI, 16.6-58.3 months) and 67% (95% CI, 30%-100%), respectively. Achieving a cCR was associated with significantly better overall survival (P=.004) and progression-free survival (P=.003). The most common grade 3 or greater toxicity during the chemotherapy phase was neutropenia. Common grade 3/4 toxicities during CCRT were nausea and vomiting. CONCLUSIONS: This regimen is tolerable and shows promising efficacy in inoperable or medically unresectable GC.
引用
- Liu Y, Zhao G, Xu Y, et al. Multicenter Phase 2 Study of Peri-Irradiation Chemotherapy Plus Intensity Modulated Radiation Therapy With Concurrent Weekly Docetaxel for Inoperable or Medically Unresectable Nonmetastatic Gastric Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 28721893. doi:10.1016/j.ijrobp.2017.03.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。